Teva Pharmaceutical Industries Stock News

Teva Pharmaceutical Industries said on Wednesday it was bracing to pay as much as $3.6 billion in cash and medicine to settle lawsuits alleging it was one of a number of drugmakers and distributors that fuelled the U.S. opioid epidemic.

NEW YORK, Feb. 9, 2022 /PRNewswire/ Full story available on Benzinga.com

Teva Pharmaceutical Industries Ltd''s (NYSE: TEVA ) Q4 sales reached $4.1 billion , shrinking 8% Y/Y, missing the consensus of $4.29 billion. The decrease is mainly due to lower revenues from generic products in North America and COPAXONE, partially offset by higher revenues from AUSTEDO and AJOVY. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic Full story available on Benzinga.com

Teva CEO Kåre Schultz joins 'The Exchange' to discuss Covid's impact on patient behavior.

Teva Pharma reported lighter-than-expected sales Wednesday as its generic drugs business and Copaxone continued to struggle. Teva stock fell.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,

https://www.investing.com/news/stock-market-news/teva-pharm-q4-profit-rises-sees-more-growth-in-key-drugs-2760316

Teva Pharmaceutical (TEVA) is trading ~1% lower on Wednesday in the pre-market after posting a mixed performance with its Q4 2021 financials

Teva Pharmaceutical Industries Ltd. (TEVA) CEO Kåre Schultz on Q4 2021 Results - Earnings Call Transcript

Shares of Teva Pharmaceutical Industries Ltd. shed 1.2% in premarket trading Wednesday, after the Israel-based generic drug maker reported fourth-quarter profit that topped expectations but revenue that missed, as COVID-19 continued to impact patient behavior and prescribing patterns. Teva swung to a net loss of $159 million, or 14 cents a share, from net income of $150 million, or 14 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 77 cents topped the FactSet consensus of 73 cents. Revenue fell 7.9% to $4.10 billion, but missed the FactSet consensus of $4.28 billion, as generic product revenue in North America and Copaxone offset higher revenue from Austedo and Ajovy. For 2022, Teva expects adjusted EPS of $2.40 to $2.60, below the FactSet consensus of $2.67, and revenue of $15.6 billion to $16.2 billion, compared with expectations of $16.1 billion. The stock has dropped 10.9% over the past three months through Tuesday, while the S&P 500 has declined 3.5%.

Teva Pharmaceutical press release (TEVA): Q4 Non-GAAP EPS of $0.77 beats by $0.04.Revenue of $4.1B (-8.9% Y/Y) misses by $180M.2022 business outlook: Revenues are expected to be $15.6…

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021. Q4 2021 and FY 2021 highlights: Q4 2021 FY 2021 Revenues $4.1 billion $15.9 billion GAAP diluted EPS $(0.14) $0.38 Non-GAAP diluted EPS $0.77 $2.58 Cash flow generated from operating activities $456 million $798 million Free cash flow $716 million $2,196 million 2022 business outlook: Revenues are expected to be $

Teva Pharmaceutical Industries Ltd's  TEVA Q4 sales reached $4.1 billion, shrinking 8% Y/Y, missing the consensus of $4.29 billion.  Get the Inside Access Traders Are Using to Profit More and Win B

Teva Pharmaceutical Industries beat fourth-quarter profit expectations as gains in North American sales of Huntington's disease treatment Austedo and migraine product Ajovy offset declines in generics